Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of the Effects of Teriparatide with those of Risedronate on Lumbar Spine Bone Mineral Density in Men and Postmenopausal Women with Low Bone Mass and a Recent Pertrochanteric Hip Fracture

Next Previous
Trial Profile

Comparison of the Effects of Teriparatide with those of Risedronate on Lumbar Spine Bone Mineral Density in Men and Postmenopausal Women with Low Bone Mass and a Recent Pertrochanteric Hip Fracture

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Teriparatide (Primary) ; Risedronic acid
  • Indications Bone resorption; Male osteoporosis; Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Acronyms MOVE
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 12 Oct 2015 Efficacy analysis (n=171) and 26 weeks interim results was presented at the 37th Annual Meeting of the American Society for Bone and Mineral Research
  • 04 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 02 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top